 |
GlaxoSmithKline Initiates $2.6 Billion Offer for Human Genome Sciences
GlaxoSmithKline (GSK) has initiated its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences (HGS) for $13.00 per share in cash, or around $2.6 billion. More... |
| |
Big Pharma Bands with Academia in $23-Million Deal
AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceutica NV, Merck Serono and Pfizer have pledged support of more than £14 million to a translational drug development project being run by the UK’s Medical Research Council and the University of Dundee. More... |
| |
ICH Q11 Drug Substance Guideline Gains Global Approval
ICH Q11, the anticipated guideline from the International Conference on Harmonisation (ICH), titled Development and Manufacture of Drug Substances, has achieved international consensus. More... |
| |
CDER Ombudsman Releases Annual Report
The US Centre for Drug Evaluation and Research Ombudsman’s office has released its annual report, which details the common questions and complaints that the office received in 2011. More... |
| |
All atweet!
Keep up to date with the latest news, gossip and rumours hitting the web about the pharmaceutical industry by following us on Twitter. More... |
|
|
|
|
| Which of these do you think is the biggest hurdle when it comes to effective quality management? |
|
Bureaucracy |
25% |
| |
|
Too many priorities |
16% |
| |
|
|
|
Lack of communication |
21% |
| |
|
|
|
Sticking to outdated traditions |
24% |
| |
|
|
|
Complacency |
14% |
This week we would like to know...
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
|
|
Contact Us
Click here to contact editorial.
Click here to contact sales. |
|
